Why Newsmax Stock Zoomed Almost 14% Higher Today
Although this was first announced several weeks ago, the shares benefited from "the index effect" on day one.
10 stocks we like better than Newsmax ›
Newsmax (NYSE: NMAX) reached a notable milestone in its brief existence as a publicly traded company on Monday, and investors reacted by snapping up shares of the stock. It closed the day nearly 14% higher in price, and with that performance absolutely thrashed the S&P 500 index's 0.5% gain.
As of Monday, Newsmax is part of both the Russell 2000 and Russell 3000 indexes. At a stroke this makes the media stock a member of both a prominent small-cap equity tracker, as part of the former index, and a component of an index that includes the largest U.S. companies with the latter.
Inclusion on (or exclusion from, while we're on the subject) an index has little if no direct effect on a company's operations and fundamentals. However there's the phenomenon of "the index effect," in which stocks can get pops simply from the free publicity and higher visibility that comes with joining a well-known index.
To a degree, this is justified. The many index funds that sniff around Russell 2000, Russell 3000, or any one of the many other stock indexes always need to be invested in component stocks. Inclusion automatically makes a company a candidate for such institutional buyers, thereby raising demand for its stock to some extent.
While Newsmax is surely glad and proud to be part of the two Russells, I should reiterate and emphasize that this development alone shouldn't sway investors toward or away from the company's stock.
It's the fundamentals that ultimately matter, and at the end of the day Newsmax will sink or swim on them. Personally, I'm not captivated by its performance and I wouldn't buy the stock just now, although the business surely has potential.
Before you buy stock in Newsmax, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Newsmax wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!*
Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Newsmax Stock Zoomed Almost 14% Higher Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Microsoft Rushes To Plug SharePoint Flaws After Wave Of Cyber Intrusions
Reports suggest that Chinese?linked hackers exploited two unpatched flaws in on?premises SharePoint to breach around 100 organizations in a single weekend. Microsoft (MFT) rushed out fixes and urged everyone to update right away. On July 19, the Microsoft Security Response Center flagged a spoofing bug (CVE?2025?49706) and a remote code execution hole (CVE?2025?49704) in on?premises SharePoint. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Advanced groups known as Linen Typhoon and Violet Typhoon have been chaining these vulnerabilities to slip into servers, and a less familiar actor called Storm?2603 is now using them too. Their favorite targets include government agencies, think tanks and universities across the U.S., Europe and East Asia. If your IT team hasn't applied the new SharePoint patches, any exposed server is at risk of having data from defense plans to donor lists stolen overnight. Microsoft pointed out that SharePoint Online in Microsoft 365 isn't affected, making the cloud version a safer bet when it comes to rapid security updates. Rolling out fixes is one thing; getting them installed in complex, custom environments is another. Until everyone catches up, expect more breach headlines. This incident is a stark reminder of why many organizations are accelerating moves from traditional on?premises software to cloud?hosted alternatives. This article first appeared on GuruFocus. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
28 minutes ago
- Yahoo
Big Alcohol prepares to fight back as buzzy cannabis drinks steal sales
By Jessica DiNapoli and Emma Rumney NEW YORK (Reuters) -Top alcohol makers have been sitting on the sidelines of a cannabis beverage boom, watching brands in the fast-growing category like Cann and Wynk make deals with beer and booze distributors, and gain valuable space on liquor store shelves. Now some alcohol companies, seeing their sales falter, are laying the groundwork to potentially enter the lucrative but risky market, a dozen founders of cannabis brands, ingredients suppliers and drinks manufacturers told Reuters. Drinks containing THC, the mood-altering ingredient in marijuana, are restricted to licensed dispensaries in 24 U.S. states where recreational use of pot is legal. But small amounts of THC can also be extracted from hemp, a crop that's related to marijuana but is legal federally. Beverages containing THC derived from hemp can be sold in many liquor shops, convenience stores and supermarkets. That's where Big Alcohol sees opportunity, despite some companies having been burned by past cannabis investments. Corona brewer Constellation Brands has been internally researching hemp-based cannabis drinks to weigh its next steps, a source familiar with the company's thinking said. Absolut vodka distiller Pernod Ricard has met with Brez, maker of drinks with THC derived from hemp, as recently as last month to discuss a possible investment, Brez's founder Aaron Nosbisch said. "They did not invest now but are circling," Nosbisch said. Pernod declined to comment on the meeting. Constellation Brands said it does not comment on rumors and speculation. Alcohol makers are still suffering a hangover following America's pandemic drinking binge, when sales spiked as cash-flush consumers splurged on pricey bottles of liquor for their homes, and then rushed back to bars when lockdown restrictions lifted. Alcohol sales have been falling ever since as inflation and interest rates rose and wallets became stretched. The companies also now face growing warnings from public health authorities who say drinking even small amounts of alcohol is associated with at least seven types of cancer. Overall U.S. beer volumes fell nearly 6% through May of this year, according to the Beer Institute. Volumes of spirits and wine sold in the same time period have declined by 5.6% and 9%, respectively, according to the Wine & Spirits Wholesalers of America. In a sign of tumult in the industry, the CEO of the world's biggest alcohol maker, Diageo, stepped down last week as the company struggles to revive growth. But hemp-based drinks are expanding fast. The market for drinks infused with THC from hemp is projected to top $1 billion in sales this year, according to market research firm Euromonitor, and climb past $4 billion in 2028. Molson Coors CEO Gavin Hattersley told Reuters in January he'd be naive to say THC beverages aren't having an effect "at least in a small way." Tilray Brands, the fourth-largest U.S. craft brewer with brands including Montauk and Shock Top, is selling its new hemp-derived THC seltzers through its beer distributors such as United Distributors in Georgia, executives told Reuters in an interview. The company's THC drinks are for sale in 13 states. "There's not a real leader that's taken ahold of the (market) so far, and that's what we look to do," Tilray's CEO Irwin Simon told Reuters earlier this year. Others, including Heineken's Lagunitas brand and Pabst Blue Ribbon, the fifth-largest U.S. brewer, have lent their names to THC seltzers for sale in dispensaries in California. Lagunitas is looking to grow distribution of its THC seltzer, potentially using hemp, to other states, a representative from Cannacraft, its ingredient supplier, said. A spokesperson for Lagunitas said it has no immediate plans to expand, but monitors market development and looks for opportunities as consumer tastes and regulations change. Boston Beer, the maker of Sam Adams, is one of the brewers with the clearest path to eventually enter the U.S. cannabis drinks market although it has not provided a time frame for doing so. The company is already selling its Teapot brand of THC-infused tea in Canada where weed is legal, and in the last year tested a potential U.S. version made from THC derived from hemp. To test the reformulated product, a panel of trained sensory experts sampled Teapot with both THC from hemp and marijuana, and could not taste a difference, said the company's head of cannabis, Paul Weaver. "This is a source of growth for our organization, flat out," Weaver said. CAUTIOUS MOVES Big Alcohol is treading carefully in cannabis drinks because state and federal regulations have shifted, and could change again, said five executives at ingredients suppliers and THC beverage brands. California, which has legal weed, banned hemp-based drinks last year to try to prevent children from consuming them. Other states have introduced special taxes or restricted sales, ambiguity that has held alcohol companies back from entering the market. Sen. Mitch McConnell, who helped first legalize hemp in 2018 to support farmers in his home state of Kentucky, in July introduced a provision in a government spending bill that could ban intoxicating products using the plant. McConnell wrote in an op-ed published in the Louisville Courier Journal on July 17 that his efforts are aimed at keeping THC gummies that look like familiar candies out of the hands of children. He did not provide comment beyond the op-ed. Big brewers have been burned by past cannabis investments. In 2022, the biggest U.S. brewer Anheuser-Busch inBev exited a deal with Tilray to research cannabis drinks in Canada. The same year, Molson Coors shuttered its U.S. business selling beverages infused with CBD, a compound in marijuana and hemp that does not have psychoactive effects, citing an uncertain regulatory environment. Constellation Brands restructured its investment in Canadian cannabis company Canopy Growth last year after poor sales. Now, however, hemp-based THC drinks are sold widely. Beyond beer's declining sales, brewers face an additional squeeze from tariffs, which threaten to push up prices for imported drinks, and Hispanic consumers, who are staying home due to fears of U.S. immigration enforcement. HIGH MARGINS Liquor stores are embracing the buzzy beverages to boost their margins as the drinks, typically more expensive than a six-pack of beer, start to outsell other types of alcohol. Jon Halper, CEO of Minnesota liquor store chain Top Ten Liquors, told Reuters in June that THC beverages now make up 15% of his business after the company introduced them two years ago. By next year, they could grow to rival wine, currently in the mid twenty percent of his sales, he said. The drinks take shelf space mostly from beer because they are in coolers, Halper said. The margins on cannabis beverages are higher than those for beer and spirits, helping his firm offset softening alcohol sales. Charleston, South Carolina-based Southern Horizon Logistics, a sister company of Budweiser distributor Southern Crown Partners, is now selling more hemp-based drinks than wine and spirits, said Justin Ashby, the company's chief administrative officer. Ryan Moses, CEO of Nashville, Tennessee-based beer, wine and spirits distributor Best Brands, said that growth from THC-infused drinks has helped offset flat and declining alcohol sales. Instead of possible layoffs, Moses has been able to re-allocate employees to the new category. "It could be as big as the other categories five to 10 years from now," Moses said. Consumers like Josh Goldberg, 39, of Lindenhurst, New York, are also trading out beer and tequila for THC seltzers. Goldberg made the switch almost two years ago, and hasn't had a drink since. "It replaces the physical act of drinking with drinking something else," Goldberg said. Halper, the owner of Minnesota liquor stores, said the customers buying THC-infused drinks tend to skew female and over the age of 35. "The soccer mom has really embraced the category in a big way," Halper said. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Corstasis Therapeutics Announces Appointment of Sanjeev Narula to its Strategic Advisory Board
HENDERSON, Nev., July 23, 2025--(BUSINESS WIRE)--Corstasis Therapeutics Inc. ( a late clinical-stage innovator of therapies that enhance options for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, with the intent of lowering the overall cost of care, today announced that life science executive Sanjeev Narula has joined the company's Strategic Advisory Board. "Sanjeev's extensive strategic, financial and operational experience in large commercial-stage pharmaceutical companies make him a tremendous addition to our strategic advisory board," said Benjamin Esque, Chairman and Chief Executive Officer of Corstasis Therapeutics Inc. "We expect Corstasis will benefit greatly from Sanjeev's advice as we prepare our commercial strategy and pre-launch activities for Enbumyst™ ahead of its potential approval in September." Mr. Narula most recently served as the Chief Financial Officer of Intra-Cellular Therapies, Inc., which he joined in 2024. During his tenure, he played a crucial role in expanding the commercial and operational capabilities of the company , which culminated in the successful acquisition of Intra-Cellular Therapies by Johnson & Johnson for $14.6 billion less than a year later. Before Intra-Cellular, Mr. Narula served as the first Chief Financial Officer of Viatris, which he joined in 2020 when the company was formed through the combination of Mylan and Upjohn, a division of Pfizer Inc. Prior to Viatris, he served as Chief Financial Officer at Upjohn, overseeing finance, procurement and business technology for all functions of the business, and held several other financial leadership positions during his 16 years at Pfizer. "I am excited to join Corstasis as a strategic advisor at this critical inflection point in the company's journey, and look forward to contributing to its growth and capital strategy as it prepares for the potential launch of Enbumyst™," said Mr. Narula. About Corstasis Therapeutics Corstasis Therapeutics is a late clinical-stage biopharmaceutical company whose mission is to develop and commercialize enhanced outpatient treatment options for patients with cardiorenal and hepatic diseases, with the intent of improving outcomes and reducing overall healthcare costs. Our lead product, Enbumyst™ bumetanide nasal spray, has been developed for the short-term treatment of edema associated with congestive heart failure, liver and kidney disease, with an anticipated PDUFA action date of September 14, 2025. For more information, please visit View source version on Contacts Ben Esque, CEOCorstasis Therapeutics 702-541-9222Email: Info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
